Lloyd-Smith Malcolm
Known title: Chief Regulatory OfficerCIK: 0001557146
Associated companies
Transaction History
| NBIX | ▼ Sell | Open Market | 701 | $73K | 2/8/2023 | View on chart |
| NBIX | ▼ Sell | Open Market | 1,015 | $104K | 2/7/2023 | View on chart |
| NBIX | ▼ Sell | Open Market | 12,801 | $1.3M | 2/7/2023 | View on chart |
| NBIX | ▼ Sell | Open Market | 801 | $85K | 2/6/2023 | View on chart |
| NBIX | ▼ Sell | Open Market | 1,666 | $183K | 1/31/2023 | View on chart |
| NBIX | ▲ Buy | Option Exercise | 3,361 | $145K | 8/15/2022 | View on chart |
| NBIX | ▲ Buy | Option Exercise | 3,455 | $124K | 8/15/2022 | View on chart |
| NBIX | ▲ Buy | Option Exercise | 1,227 | $100K | 8/15/2022 | View on chart |
| NBIX | ▲ Buy | Option Exercise | 21,533 | $775K | 8/12/2022 | View on chart |
| NBIX | ▼ Sell | Open Market | 21,533 | $2.3M | 8/12/2022 | View on chart |
| NBIX | ▼ Sell | Open Market | 701 | $56K | 2/8/2022 | View on chart |
| NBIX | ▼ Sell | Open Market | 865 | $70K | 2/7/2022 | View on chart |
| NBIX | ▼ Sell | Open Market | 1,015 | $82K | 2/7/2022 | View on chart |
| NBIX | ▼ Sell | Open Market | 801 | $65K | 2/7/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
NBIX Faces Mixed Analyst Views Amid CAH Data Presentation
Neurocrine Biosciences is presenting real-world data on congenital adrenal hyperplasia at an upcoming medical symposium. While Needham reiterated a positive stance with a $204 target, BMO Capital lowered its target to $150, reflecting a wide range of analyst expectations. The stock is currently trading near its support level, with the average analyst target remaining well above the current price.
NBIX Faces Mixed Analyst Views Amid CAH Data Presentation. Neurocrine Biosciences is presenting real-world data on congenital adrenal hyperplasia at an upcoming medical symposium. While Needham reiterated a positive stance with a $204 target, BMO Capital lowered its target to $150, reflecting a wide range of analyst expectations. The stock is currently trading near its support level, with the average analyst target remaining well above the current price.